Top Stories
The FDA placed a clinical hold on the Phase III HERO trial of ARD-101, while Cabaletta said three patients with pemphigus vulgaris who skipped a preconditioning regimen still achieved B cell depletion.
The pharma will use Tempus' Lens platform to pressure-test trial assumptions and stratify patient groups across five initial programmes spanning solid tumours and Alzheimer's disease.
The biotech is advancing a CD19-targeted cell therapy, as well as a dual-targeting CD19/BCMA programme.
The Phase III AFFINITY DUCHENNE study of RGX-202 linked microdystrophin expression data with one-year functional outcomes.
The company plans to move diranersen into registrational development.
Conference News
HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (A...
TOKYO--(BUSINESS WIRE)-- Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one o...
Findings point to continued momentum toward combination therapies that target the full pathobiology of the diseaseNEW YORK, May 14, 2026 /PRNewswire/ -- Today, Biogen announced topline results from th...
UCLA researchers and surgeons will present on the world’s first human bladder transplant and the latest findings on prostate cancer, Peyronie’s Disease, endothelial health and other related topics at ...
Researchers are also investigating other potential actions of obesity drugs on blood pressure that go beyond weight lossA meta-analysis of 32 studies and 43,618 adults presented at this year’s Europea...
